Evidence map›Paper›PMID 28752102›Full record

ArticleOpen forum infectious diseases2017

Acute Kidney Injury and Urinary Biomarkers in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis.

Charlotte Schutz, David R Boulware, Katherine Huppler-Hullsiek, Maximilian von Hohenberg, Joshua Rhein, Kabanda Taseera, Friedrich Thienemann, Conrad Muzoora, David B Meya, Graeme Meintjes

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Cryptococcal meningitis.Nature reviews. Disease primers · 2023
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Charlotte SchutzDepartment of Medicine, Faculty of Health Sciences, and.
David R BoulwareDivision of Infectious Diseases & International Medicine, Department of Medicine, and.
Katherine Huppler-HullsiekDivision of Biostatistics, School of Public Health, University of Minnesota, Minneapolis.
Maximilian von HohenbergDivision of Infectious Diseases & International Medicine, Department of Medicine, and.
Joshua RheinDivision of Infectious Diseases & International Medicine, Department of Medicine, and.
Kabanda TaseeraMbarara University of Science and Technology, Mbarara, and.
Friedrich ThienemannDepartment of Medicine, Faculty of Health Sciences, and.
Conrad MuzooraMbarara University of Science and Technology, Mbarara, and.
David B MeyaDivision of Infectious Diseases & International Medicine, Department of Medicine, and.
Graeme MeintjesDepartment of Medicine, Faculty of Health Sciences, and.
Office of Infectious Diseases · USMbarara University of Science and Technology · UGWellcome Centre for Infectious Diseases Research in Africa · ZAMakerere University · UGUniversity of Cape Town · ZAUniversity of Minnesota · US

Funding

Trial for the Optimal Timing of HIV Therapy after Cryptococcal MeningitisU01AI089244 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R · 2010 to 2014
$7.6M
Infectious Disease Training in Clinical InvestigationT32AI055433 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI David R Boulware · 2003 to 2026
$6.1M
South Africa Tuberculosis/AIDS TrainingU2RTW007373 · FIC · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VAN DER HORST, CHARLES MICHAEL · 2007 to 2012
$1.4M
Improving Outcomes of HIV-Associated Cryptococcosis in Resource-Limited SettingsK01TW010268 · FIC · UNIVERSITY OF MINNESOTA · PI RHEIN, JOSHUA R · 2016 to 2020
$703k
FIC NIH HHS K01 TW010268FIC NIH HHS U2R TW007373NIAID NIH HHS T32 AI055433NIAID NIH HHS U01 AI089244Wellcome Trust 081667Wellcome Trust 098316
6 · The paper itself

Abstract

background

methodsOne hundred and thirty human immunodeficiency virus (HIV)-infected participants with cryptococcal meningitis were enrolled and received amphotericin and fluconazole for 2 weeks. We defined AKI as glomerular filtration rate (GFR) < 60 mL/min/1.73 m

resultsParticipants were 48% female with a median age of 35 years, a median CD4 count of 21 cells/μL, and 44% died within 12 months. Incident AKI occurred in 42% and was associated with mortality (adjusted hazard ratio [aHR] = 2.8;

conclusionsAcute kidney injury occurred in 42% of patients, and AKI was associated with mortality. Urine biomarkers, specifically urine protein, may be useful for antecedent prediction of amphotericin-associated AKI but need further evaluation.

Indexed as

acute kidney injuryamphotericin Bbiological markercystatin Cneutrophil gelatinase-associated lipocalinproteintissue inhibitor of metalloproteinase-2

Identifiers

PMID28752102
PMCPMC5527271
OpenAlexW2677706917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.